Bal Pharma Limited (BALPHARMA) — FY26 Annual Report | 26 August 2026

26 August 2026 · NSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

39th AGM scheduled for September 24, 2026 via video conference with dividend record date September 17, 2026.

🔄 What Changed

Rs 1.20 per share final dividend declared; Ravindra Kumar Kothari re-designated Whole-Time Director; Virupakshaya Himesh re-designated Non-Executive Director; related party contract with Desa Marketing International renewed up to Rs 30 crore annually.

🔮 What's Next

The company will continue to focus on pharma manufacturing, marketing, and export promotion through its renewed agreement with Desa Marketing International, and leverage Kothari's operational expertise as Whole-Time Director to drive growth.

💡 Investor Takeaway

Shareholders must vote on key governance changes and related party transactions that could affect future profitability and management structure.

Bal Pharma Limited announced its 39th Annual General Meeting on September 24, 2026, via video conference, with record date September 17, 2026 for final dividend of Rs 1.20 per share. Shareholders will vote on adopting audited financial statements, declaring the dividend, reappointing directors, ratifying cost auditor remuneration, renewing a related party contract with Desa Marketing International up to Rs 30 crore annually, and changing designations of Ravindra Kumar Kothari to Whole-Time Director and Virupakshaya Himesh to Non-Executive Director. E-voting opens September 21-23, 2026.

📄 View Original Announcement (PDF)

📊 Stock Analysis — BALPHARMA ✨ Ask AI About This

About Bal Pharma Limited (BALPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹177.95 CrP/E: 24.6ROE: 8.8%ROCE: 10.0%Div Yield: 1.07%

View full BALPHARMA stock details →

📡 Get AI alerts when BALPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track BALPHARMA — Free

💡 Ask AI about this filing

"What is the expected impact of the new Whole-Time Director role on profitability?""How does the Rs 30 crore related party contract compare to peers?""What is the projected dividend yield based on current share price?"

Ask AI Free →

📊 More BALPHARMA filings

Announcement — 25 September 2026Bal Pharma Ltd announced the closure of its trading window effective October 1, 2026, until 48 hours...
🟡 Board Meeting — 25 September 2026Bal Pharma announced at its September 24, 2026 AGM the re-appointment of Ravindra Kumar Kothari as D...
🟡 Board Meeting — 24 September 2026Bal Pharma held its 39th AGM on September 24, 2026, approving a Rs. 1.20 per share dividend for FY20...
Announcement — 10 September 2026Bal Pharma clarified that recent price volatility in its shares is market-driven with no price-sensi...
🔴 Corporate Action — 7 September 2026Bal Pharma announced the allotment of 10 lakh convertible warrants to promoter Shailesh Siroya at ₹8...

See all BALPHARMA filings →

🔥 Also filed on 26 August 2026

ORIENTCEMOrient Cement LimitedCorporate Action IRBIRB Infrastructure Developers LimitedCorporate Action EUROTEXINDEurotex Industries and Exports LimitedAnnual Report INNOVISIONInnovision LimitedAnnouncement MOLDTECHMold-Tek Technologies LimitedCorporate Action MOTHERSONSamvardhana Motherson International LimitedCorporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when BALPHARMA files new disclosures

Track BALPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.